0000000000174488

AUTHOR

Joan Puig-barberà

0000-0001-5783-0409

showing 8 related works from this author

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pne…

2007

Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case-control studies were performed during the 2004-2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n=105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for p…

Relative risk reductionSqualeneAcute coronary syndromemedicine.medical_specialtyInfluenza vaccinePopulationPolysorbatesMass VaccinationAdjuvants ImmunologicRisk FactorsInternal medicinemedicineHumanseducationAgedAged 80 and overeducation.field_of_studyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryRespiratory diseasePublic Health Environmental and Occupational HealthOdds ratioPneumoniamedicine.diseaseVaccinationHospitalizationPneumoniaCerebrovascular DisordersInfectious DiseasesCardiovascular DiseasesInfluenza VaccinesSpainCase-Control StudiesImmunologyVaccines SubunitMolecular MedicinebusinessVaccine
researchProduct

Influenza control in the 21st century: Optimizing protection of older adults

2009

Older adults (> or =65 years of age) are particularly vulnerable to influenza illness. This is due to a waning immune system that reduces their ability to respond to infection, which leads to more severe cases of disease. The majority ( approximately 90%) of influenza-related deaths occur in older adults and, in addition, catastrophic disability resulting from influenza-related hospitalization represents a significant burden in this vulnerable population. Current influenza vaccines provide benefits for older adults against influenza; however, vaccine effectiveness is lower than in younger adults. In addition, antigenic drift is also a concern, as it can impact on vaccine effectiveness due t…

DiseaseVaccines AttenuatedAntigenic driftDNA vaccinationAdjuvants ImmunologicCost of IllnessImmunityInfluenza HumanHumansMedicineAntigens ViralAgedAttenuated vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryHealth PolicyImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaccines VirosomeVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicinebusinessVaccine
researchProduct

Effectiveness of the 2010–2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: A case–case comparison, case-…

2012

Highlights ► We perform a case–case comparison as an improvement of the test-negative design. ► We report IVE estimates with a low probability of bias. ► Influenza vaccination halved the risk of confirmed influenza hospitalization. ► This effect was consistent regardless of age over 60. ► The measured effect was specific for confirmed influenza hospitalizations.

AdultMalemedicine.medical_specialtyAdolescentInfluenza vaccineCase-control studiesArticleSeasonal influenzaYoung AdultInfluenza Human/epidemiologyInternal medicineInfluenza HumanMedicineHumansProspective StudiesYoung adultProspective cohort studyIntensive care medicineReverse transcriptase polymerase chain reactionAgedHospitalizationsGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryCase comparisonVaccinationPublic Health Environmental and Occupational HealthCase-control studyvirus diseasesMiddle AgedConfidence intervalVaccinationHospitalizationInfectious DiseasesInfluenza vaccinesRisk factorsVaccines InactivatedSpainMolecular MedicineFemalebusinessRespiratory syncytial virus infections/epidemiologyVaccine
researchProduct

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

2011

Background: Heptavalent pneumococcal conjugate vaccine (PCV-7) was licensed to provide immunity against pneumococcal disease caused by seven serotypes of S. pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV-13) includes 6 additional serotypes for preventing invasive pneumococcal disease. Objective: The objective of this study was to estimate the potential health benefits, costs, and cost-effectiveness of vaccination with PCV-13 in the Community of Valencia and to generate valuable information for policy makers at regional and country levels. Methods: A decision tree was designed to determine the health and economic outcomes in hypothetical cohorts of vaccinated and unvaccinate…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCost effectivenessPharmacoeconomic assessmentCost-Benefit AnalysisPneumococcal conjugate vaccinePneumococcal InfectionsHerd immunityPneumococcal VaccinesIndirect costsYoung AdultEnvironmental healthmedicineHeptavalent Pneumococcal Conjugate VaccineHumansChildAgedAged 80 and overGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPneumococcal conjugate vaccineVaccinationPublic Health Environmental and Occupational HealthInfant NewbornInfantMiddle AgedQuality-adjusted life yearVaccinationInfectious DiseasesSpainChild PreschoolCohortMolecular MedicineCost-effectivenessFemalebusinessmedicine.drugVaccine
researchProduct

Pertussis in adults with persistent cough: a prospective follow up study in primary care.

2009

Despite high coverage of pertussis vaccine, B. pertussis has remained endemic and adults are recognized as reservoir for infection among incompletely immunized infants. Between November 15th 2004 and November 14th 2006, 37 general practitioners, attending 56,658 adults, recruited all patients with persistent cough. A diagnosis of pertussis was considered in those with an unexplained cough, lasting 14 or more days and a positive polymerase chain reaction (PCR) or enzyme-linked immunosorbent assay (ELISA) IgG anti-Pertussis Toxin (PT). During the period of the study 86 patients presented with persistent cough (106 cases per 100,000 person-years). According to laboratory criteria, 35% were cla…

Bordetella pertussismedicine.medical_specialtyImmunologyWhooping-cough-epidemiologyPharmaceutical SciencePrimary careHigh coverageBordetella pertussisAntibodiesInternal medicineDrug DiscoveryPersistent coughMedicineAdultsPrimary Carebiologybusiness.industryIncidence (epidemiology)Follow up studiesbiology.organism_classificationInfectious DiseasesImmunologybiology.proteinPertussis vaccineAntibodybusinessmedicine.drug
researchProduct

2011–12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hos…

2013

BackgroundInfluenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estimating the effectiveness of seasonal vaccines against influenza related hospitalisation is important to guide these strategies. Large sample size is needed to have precise estimate of influenza vaccine effectiveness (IVE) against severe outcomes. We assessed the feasibility of measuring seasonal IVE against hospitalisation with laboratory confirmed influenza through a network of 21 hospitals in the European Union.MethodsWe conducted a multicentre study in France (seven hospitals), Italy (one hospital), and Navarra (four hospitals) and Valencia (nine hospitals) regions in Spain. All ≥1…

MaleViral DiseasesEpidemiologyPilot ProjectsLogistic regressionmedicine.disease_cause0302 clinical medicineInfluenza A virusClinical Epidemiology030212 general & internal medicineEpidemiological Methodsmedia_commonAged 80 and overeducation.field_of_studyVaccinesMultidisciplinaryQVaccinationREpidemiology of AgingMiddle Aged3. Good healthVaccinationHospitalizationInfectious DiseasesInfluenza VaccinesMedicineFemaleSeasonsResearch ArticleAdultmedicine.medical_specialtyAdolescentInfluenza vaccineClinical Research DesignScience030231 tropical medicinePopulationMicrobiologyHistory 21st CenturyInfectious Disease Epidemiology03 medical and health sciencesYoung AdultInternal medicineVirologyVaccine DevelopmentInfluenza Humanmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationBiologyAgedbusiness.industryInfluenza A Virus H3N2 SubtypeCase-control studyImmunityViral VaccinesInfluenzaSample size determinationCase-Control StudiesImmunologyClinical ImmunologybusinessPLoS ONE
researchProduct

Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influ…

2016

Abstract Background Continuous surveillance for genetic changes in circulating influenza viruses is needed to guide influenza prevention and control. Objectives To compare intra-seasonal influenza genetic diversity of hemagglutinin in influenza A strains isolated from influenza hospital admissions collected at two distinct sites during the same season. Study design Comparative phylogenetic analysis of full-length hemagglutinin genes from 77 isolated influenza A viruses from the St. Petersburg, Russian Federation and Valencia, Spain sites of the Global Influenza Hospital Surveillance Network (GIHSN) during the 2013/14 season. Results We found significant variability in A(H3N2) and A(H1N1)pdm…

0301 basic medicineHemagglutinin glycoproteinsMalevirusesHemagglutinin Glycoproteins Influenza Virusmedicine.disease_causeGlobal HealthRussia0302 clinical medicineGenomic sequencingInfluenza A Virus H1N1 SubtypeInfluenza A virusH3N2 subtype030212 general & internal medicineCladeChildPhylogenyAged 80 and overPhylogenetic treevirus diseasesMiddle AgedInfectious DiseasesInfluenza A virusChild PreschoolEpidemiological MonitoringRNA ViralFemaleSeasonsAdultAdolescentHemagglutinin (influenza)Genome ViralBiologyH5N1 genetic structure03 medical and health sciencesYoung AdultVirologyInfluenza preventionGenetic variationInfluenza HumanmedicineHumansAgedGenetic diversityInfluenza A Virus H3N2 SubtypeGenetic VariationInfantSequence Analysis DNAVirology030104 developmental biologyH1N1 subtypeSpainbiology.proteinInfluenza virusJournal of Clinical Virology
researchProduct

Retrospective screening for SARS-CoV-2 among influenza-like illness hospitalizations: 2018-2019 and 2019-2020 seasons, Valencia region, Spain

2021

Este artículo se encuentra disponible en la siguiente URL: https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.12899 En este artículo de investigación también participan: Juan Mollar-Maseres, Germán Schwarz-Chavarri, Sandra García-Esteban, Joan Puig-Barberà, Javier Díez-Domingo y F. Xavier López-Labrador. On 9 March 2020, the World Health Organization (WHO) Global Influenza Programme (GIP) asked participant sites on the Global Influenza Hospital Surveillance Network (GIHSN) to contribute to data collection concerning severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We re-analysed 5833 viral RNA archived samples collected prospectively from hospital admissions for influenza-lik…

Pulmonary and Respiratory Medicinemedicine.medical_specialty2019-20 coronavirus outbreakRT‐PCRSARS-CoV-2 (Virus) - Diagnóstico - 2018-2019 - España - Valencia (Comunidad Valenciana)EpidemiologyShort CommunicationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationShort CommunicationscoronavirusData analysis.COVID-19 - Diagnóstico - 2019-2020 - España - Valencia (Comunidad Autónoma)medicine.disease_causeWorld healthCOVID‐19Influenza HumanPandemicmedicineHumansCOVID-19 - Diagnóstico - 2018-2019 - España - Valencia (Comunidad Autónoma)Influenza - Diagnosis - 2019-2020 - Spain - Valencia (Autonomous Community)Viral rnaGripe - Diagnóstico - 2018-2019 - España - Valencia (Comunidad Autónoma)influenza‐like‐illnesseducationRetrospective StudiesCoronaviruseducation.field_of_studyInfluenza-like illnessSARS-CoV-2business.industrySARS-CoV-2 (Virus) - Diagnosis - 2018-2019 - Spain - Valencia (Autonomous Community)COVID-19 (Disease) - Diagnosis - 2019-2020 - Spain - Valencia (Autonomous Community)Public Health Environmental and Occupational HealthCOVID-19virus diseasesCOVID-19 (Disease) - Diagnosis - 2018-2019 - Spain - Valencia (Autonomous Community)Análisis de datos.HospitalizationSARS-CoV-2 (Virus) - Diagnóstico - 2019-2020 - España - Valencia (Comunidad Valenciana)Infectious DiseasesInfluenza - Diagnosis - 2018-2019 - Spain - Valencia (Autonomous Community)SpainGripe - Diagnóstico - 2019-2020 - España - Valencia (Comunidad Autónoma)Emergency medicineSARS-CoV-2 (Virus) - Diagnosis - 2019-2020 - Spain - Valencia (Autonomous Community)Seasonsbusiness
researchProduct